Showing results (31-40 of 122) with videos related to

Sort By:
Pageof 13
Clinical Genitourinary Cancer|September 6, 2016
A Suggested Prognostic Reclassification of Intermediate and Poor-Risk Nonseminomatous Germ Cell TumorsAndrea Necchi, Gregory R Pond, Nicola Nicolai, et al.
Frontiers in Oncology|September 22, 2022
Immunotherapy in advanced kidney cancer: an alternative meta-analytic method using reconstructed survival data in case of proportional hazard assumption violationLuigi Nocera, Giuseppe Fallara, Daniele Raggi, et al.
European Urology|May 31, 2021
Is There a Detrimental Effect of Antibiotic Therapy in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Pembrolizumab?Filippo Pederzoli, Marco Bandini, Daniele Raggi, et al.
Clinical Genitourinary Cancer|October 5, 2015
Interim (18)F-Fluorodeoxyglucose Positron Emission Tomography for Early Metabolic Assessment of Response to Cisplatin, Etoposide, and Bleomycin Chemotherapy for Metastatic Seminoma: Clinical Value and Future DirectionsAndrea Necchi, Nicola Nicolai, Alessandra Alessi, et al.
Bladder Cancer (Amsterdam, Netherlands)|March 4, 2025
Antiangiogenic therapy combined with immune checkpoint blockade in urothelial cancer: Systematic review and meta-analysisMohammad Jad Moussa, Iuliia Kovalenko, Emanuele Crupi, et al.
International Journal of Cancer|March 15, 2021
Renal function outcomes in patients with muscle-invasive bladder cancer treated with neoadjuvant pembrolizumab and radical cystectomy in the PURE-01 studyFrancesco Trevisani, Federico Di Marco, Daniele Raggi, et al.
Critical Reviews in Oncology/Hematology|August 28, 2022
Androgen annihilation versus advanced androgen blockage as first line treatment for metastatic castration resistant prostate cancer: A systematic review and meta-analysisGiuseppe Fallara, Federico Belladelli, Daniele Robesti, et al.
Bone Marrow Transplantation|January 26, 2018
Secondary malignancies after high-dose chemotherapy in germ cell tumor patients: a 34-year retrospective study of the European Society for Blood and Marrow Transplantation (EBMT)Andrea Necchi, Salvatore Lo Vullo, Simona Secondino, et al.
Urologic Oncology|July 24, 2021
Molecular subtyping and immune-gene signatures identify a subset of early bladder tumors as candidates for single-agent immune-checkpoint inhibitionAndrea Necchi, Daniele Raggi, Andrea Gallina, et al.
Cancer Treatment Reviews|February 17, 2022
Immunotherapy versus chemotherapy as first-line treatment for advanced urothelial cancer: A systematic review and meta-analysisAlberto Martini, Daniele Raggi, Giuseppe Fallara, et al.
Pageof 13